Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tianlong Cough and Asthma Capsule is a proprietary Chinese medicine (TCM) developed by The First Affiliated Hospital of Guangzhou Medical University. It is specifically formulated for the treatment of chronic obstructive pulmonary disease (COPD), particularly during the stable period of the disease. The medication is intended to alleviate clinical symptoms such as cough and asthma by leveraging the synergistic effects of its traditional herbal components. Clinical research, including a multicenter, randomized, double-blind, placebo-controlled trial (ChiCTR-IIR-17011606), has been conducted to evaluate its long-term efficacy and safety profile, providing a theoretical and clinical basis for its potential market entry as a new proprietary Chinese medicine for obstructive pulmonary diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tianlong Cough and Asthma Capsule (The First Affiliated Hospital of Guangzhou Medical University).